BioSphere Medical, Inc. (NASDAQ:BSMD) (“BioSphere” or the “Company”) – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – reported financial results for the three and nine months ended

Related posts

Unigene Reports Financial Results for Fourth Quarter and [...]

Continue reading " BioSphere Medical Reports Third Quarter Revenue of $7.69 Million and a Narrowed Net Loss of $0.02 Per Share "

BioSphere Medical, Inc. (NASDAQ:BSMD), the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, announced that it plans to issue its financial results for the third quarter ended September 30, 2009 on October 28 after the close of the [...]

Continue reading " BioSphere Medical Schedules Third Quarter 2009 Financial Results Conference Call October 29 "